Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Pluristem Therapeutics (PSTI)
NASDAQ:PSTI
Pluristem (PSTI) Stock Price & Analysis
0 Followers
PSTI Stock Chart & Stats
Day’s Range$0.95 - $1.05
52-Week Range― - ―
Previous Close$1.03
Volume170.63K
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding32,347,584
10 Day Avg. Volume109,652
30 Day Avg. Volume80,184
Standard Deviation0.25
R-Squared0.14
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.87
Price to Sales (P/S)142.38
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-1.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.00Price Target Upside600.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Pluristem News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PSTI FAQ
What was Pluristem Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Pluristem Therapeutics’s market cap?
Currently, no data Available
When is Pluristem Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Pluristem Therapeutics’s earnings last quarter?
Currently, no data Available
Is Pluristem Therapeutics overvalued?
According to Wall Street analysts Pluristem Therapeutics’s price is currently Undervalued.
Does Pluristem Therapeutics pay dividends?
Pluristem Therapeutics does not currently pay dividends.
What is Pluristem Therapeutics’s EPS estimate?
Pluristem Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pluristem Therapeutics have?
Currently, no data Available
What happened to Pluristem Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pluristem Therapeutics?
Among the largest hedge funds holding Pluristem Therapeutics’s share is ARK Investment Management LLC. It holds Pluristem Therapeutics’s shares valued at N/A.
---
Pluristem Stock Smart Score
Company Description
Pluristem Therapeutics
Pluristem Therapeutics, Inc. engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. It focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.
---
Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.
---